Portfolio

Biopharmaceutical company developing desensitization treatments for food allergies

Biotechnology company developing novel oncology therapeutics based on a deep understanding of the human immune response

Biomea Fusion is a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers. Leveraging its extensive expertise in irreversible binding chemistry and development, the Company built its proprietary FUSION System discovery platform to advance a pipeline of novel irreversible, small molecule therapies. The lead product candidate, BMF-219, is an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Biomea Fusion’s goal is to utilize its capabilities and platform to become a leader in developing irreversible small molecules in order to maximize the depth and durability of clinical benefit when treating various cancers.

Orphan disease drug platform with a robust portfolio of transformative drug programs that address rare diseases across oncology, cardiology, dermatology, neurology and endocrinology

Drug discovery and development company focused on devastating fungal infections that often complicate cancer and transplant treatments

Biopharmaceutical company developing therapies to treat transthyretin amyloidosis (ATTR), primarily in the heart

Biotechnology company developing topical therapeutics targeting rare dermatological diseases

Biopharmaceutical company developing next-generation CAR-T therapies for hematological cancers and solid tumors.

Biopharmaceutical company developing and marketing human milk-based nutritional products for premature infants in the neonatal intensive care unit

Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation and may increase production of new mitochondria.

Spruce is a clinical stage biopharmaceutical company developing therapeutics for rare endocrine diseases. Spruce's lead product, tildacerfont, is in late-stage development for classic congenital adrenal hyperplasia (CAH).

Biopharmaceutical company developing oncology therapeutics for the treatment of solid and hematologic cancers

Biopharmaceutical company developing a novel patch formulation of zolmitriptan for the treatment of acute migraine